Romosozumab ‘safe and effective’ in women with osteoporosis and CKD

A post-hoc analysis shows the biologic reduced fracture risk with similar adverse event rates across a range of renal function levels

Postmenopausal women with comorbid osteoporosis and mild-to-moderate chronic kidney disease can safely be prescribed romosozumab, US-led researchers say.

Their findings suggest that the monoclonal antibody remains highly effective across varying levels of renal function down to an eGFR of 30mL/min/1.73m2.